Samsung Biologics, the biotech arm of Samsung, said Monday that its contract manufacturing organization (CMO) deals have exceeded 3 trillion won ($2.2 billion) so far this year.
Samsung Biologics has secured five biomanufacturing contracts, bringing the total of its 2023 orders to over 3 trillion won for the first time since its foundation.
Samsung Biologics posted a consensus-beating 320 billion won ($240 million) in operating profit in the third quarter, with revenues surpassing 1 trillion won for the first time in its history.
Samsung Biologics raised its revenue forecast for the year to $2.65 billion, citing new contract manufacturing deals and increased production capabilities.
Samsung Biologics secures a $242 million contract manufacturing deal with Bristol-Myers Squibb, boosting its total contract wins this year to nearly $2.26 billion.
Samsung Biologics inked a $411 million contract manufacturing organization (CMO) letter of intent with Pfizer Ireland Pharmaceuticals, the biggest single deal the Korean company ever signed.
Samsung Biologics inked a $112.5 million contract manufacturing organization (CMO) letter of intent with an unnamed U.S. biopharmaceutical firm, the Korean company said in a regulatory filing on Monday.
Samsung Biologics logged a weaker-than-expected profit in the first quarter, mainly due to an extraordinary item.
Samsung Biologics reported a 103 percent surge in net profit in 2022, with revenues and operating profit hitting records.
Lotte Biologics signed a memorandum of understanding (MOU) with Huons Global to manufacture the Pangyo, Gyeonggi-based company's biopharmaceuticals.
Korea JoongAng Daily Sitemap
